Search

Your search keyword '"Tang, Chuanhao"' showing total 178 results
Start Over Author "Tang, Chuanhao"
178 results on '"Tang, Chuanhao"'

5. Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations

Author

Wang, Wenxian, Lian, Bin, Xu, Chunwei, Wang, Qian, Li, Ziming, Zheng, Nan, Liu, Aijun, Yu, Jinpu, Zhong, Wenzhao, Wang, Zhijie, Zhang, Yongchang, Liu, Jingjing, Zhang, Shirong, Cai, Xiuyu, Liu, Anwen, Li, Wen, Mao, Lili, Zhan, Ping, Liu, Hongbing, Lv, Tangfeng, Miao, Liyun, Min, Lingfeng, Chen, Yu, Yuan, Jingping, Wang, Feng, Jiang, Zhansheng, Lin, Gen, Huang, Long, Pu, Xingxiang, Lin, Rongbo, Liu, Weifeng, Rao, Chuangzhou, Lv, Dongqing, Yu, Zongyang, Li, Xiaoyan, Tang, Chuanhao, Zhou, Chengzhi, Zhang, Junping, Xue, Junli, Guo, Hui, Chu, Qian, Meng, Rui, Liu, Xuewen, Wu, Jingxun, Zhang, Rui, Zhou, Jin, Zhu, Zhengfei, Li, Yongheng, Qiu, Hong, Xia, Fan, Lu, Yuanyuan, Chen, Xiaofeng, Feng, Jian, Ge, Rui, Dai, Enyong, Han, Yu, Pan, Weiwei, Pang, Fei, Huang, Xin, Hu, Meizhen, Hao, Qing, Wang, Kai, Wu, Fan, Song, Binbin, Xu, Bingwei, Wang, Liping, Zhu, Youcai, Lin, Li, Xie, Yanru, Lin, Xinqing, Cai, Jing, Xu, Ling, Li, Jisheng, Jiao, Xiaodong, Li, Kainan, Wei, Jia, Feng, Huijing, Wang, Lin, Du, Yingying, Yao, Wang, Shi, Xuefei, Niu, Xiaomin, Yuan, Dongmei, Yao, Yanwen, Huang, Jianhui, Feng, Yue, Zhang, Yinbin, Sun, Pingli, Wang, Hong, Ye, Mingxiang, Wang, Dong, Wang, Zhaofeng, Hao, Yue, Wang, Zhen, Wan, Bin, Lv, Donglai, Yang, Shengjie, Kang, Jin, Zhang, Jiatao, Zhang, Chao, Li, Wenfeng, Fu, Jianfei, Wu, Lizhi, Lan, Shijie, Ou, Juanjuan, Shi, Lin, Zhai, Zhanqiang, Wang, Yina, Li, Bihui, Zhang, Zhang, Wang, Ke, Ma, Xuelei, Li, Zhongwu, Liu, Zhefeng, Yang, Nong, Wu, Lin, Wang, Huijuan, Jin, Gu, Wang, Guansong, Wang, Jiandong, Shi, Hubing, Fang, Meiyu, Fang, Yong, Li, Yuan, Wang, Xiaojia, Chen, Jing, Zhang, Yiping, Zhu, Xixu, Shen, Yi, Ma, Shenglin, Wang, Biyun, Song, Yong, Song, Zhengbo, Fang, Wenfeng, Lu, Yuanzhi, and Si, Lu

Published
2024
Full Text
View/download PDF

9. A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis

Author

ZHANG Lingling, WANG Xiangyi, WEI Xing, LIN Li, TANG Chuanhao, LIANG Jun

Subjects
low-frequency electrical acupoint stimulation, nausea and vomiting, chemotherapy, non-small cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background and purpose: In patients with advanced non-small cell lung cancer (NSCLC) who receive platinum-containing dual-drug chemotherapy with high emetic risk, a significant number of patients experience nausea and vomiting after chemotherapy, even if they are treated with a triple or quadruple antiemetic regimen. The low-frequency electrical stimulator for antiemesis is a wearable electronic antiemesis device, which can effectively reduce nausea and vomiting caused by various reasons. However, no studies have investigated whether the combination of three antiemetic drugs with low-frequency electrical stimulator can further improve the control rate of chemotherapy-induced nausea and vomiting (CINV). Therefore, the aim of this study was to assess the efficacy and tolerability of low-frequency electrical stimulator for antiemesis plus standard antiemetics following highly emetogenic chemotherapy in patients with NSCLC. Methods: Data of patients with advanced NSCLC who received first-line hyperemetic chemotherapy at Peking University International Hospital from December 1, 2019 to December 30, 2022 were retrospectively collected. Patients who correctly wore low-frequency electrical stimulator for antiemesis were selected as the observation group, and chemotherapy patients who did not wear low-frequency electrical stimulator were selected as the control group. Clinical characteristics, occurrence of nausea and vomiting after chemotherapy and functional living index-emesis (FLIE) questionnaire were collected. SPSS 20.0 was used for statistical analysis to compare the vomiting complete response rate, nausea incidence and FLIE score between the two groups. Results: Compared with the control group, the no nausea rate (66.3% vs 51.1%, P=0.036) and the complete response rate of vomiting (83.7% vs 66.3%, P=0.006) in experimental group were significantly increased. At 24-120 h after chemotherapy, the complete response rate of vomiting at the delayed stage increased conspicuously in the observation group (88.0% vs 69.6%, P=0.002). At this stage, the proportion of patients without nausea in the observation group was also significantly higher (73.9% vs 57.6%, P=0.020). The total FLIE scores were conspicuously higher in the observation group than in the control group (106.05±15.35 vs 95.04±20.02, P=0.020). Conclusion: The results suggest that, on the basis of the triple antiemesis regimen, wearing the low-frequency electrical stimulator can significantly improve the control level of CINV and the quality of life of NSCLC patients, which can be an effective supplement to the triple antiemesis regimen.

Published
2023
Full Text
View/download PDF

10. Chinese expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2022 edition)

Author

Duan, Jianchun, Fang, Wenfeng, Xu, Hairong, Wang, Jinliang, Chen, Yuan, Ding, Yi, Dong, Xiaorong, Fan, Yun, Gao, Beili, Hu, Jie, Huang, Yan, Huang, Cheng, Huang, Dingzhi, Liang, Wenhua, Lin, Lizhu, Liu, Hui, Ma, Zhiyong, Shi, Meiqi, Song, Yong, Tang, Chuanhao, Wang, Jialei, Wang, Lifeng, Wang, Yongfeng, Wang, Zhehai, Yang, Nong, Yao, Yu, Yu, Yan, Yu, Qitao, Zhang, Hongmei, Zhao, Jun, Zhao, Mingfang, Zhu, Zhengfei, Niu, Xiaohui, Zhang, Li, and Wang, Jie

Published
2023
Full Text
View/download PDF

15. Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors

Author

Xu, Chunwei, additional, Wang, Qian, additional, Wang, Dong, additional, Wang, Wenxian, additional, Fang, Wenfeng, additional, Li, Ziming, additional, Liu, Aijun, additional, Yu, Jinpu, additional, Zhong, Wenzhao, additional, Wang, Zhijie, additional, Zhang, Yongchang, additional, Liu, Jingjing, additional, Zhang, Shirong, additional, Cai, Xiuyu, additional, Liu, Anwen, additional, Li, Wen, additional, Zhan, Ping, additional, Liu, Hongbing, additional, Lv, Tangfeng, additional, Miao, Liyun, additional, Min, Lingfeng, additional, Chen, Yu, additional, Yuan, Jingping, additional, Wang, Feng, additional, Jiang, Zhansheng, additional, Lin, Gen, additional, Huang, Long, additional, Pu, Xingxiang, additional, Lin, Rongbo, additional, Liu, Weifeng, additional, Rao, Chuangzhou, additional, Lv, Dongqing, additional, Yu, Zongyang, additional, Li, Xiaoyan, additional, Tang, Chuanhao, additional, Zhou, Chengzhi, additional, Zhang, Junping, additional, Xue, Junli, additional, Guo, Hui, additional, Chu, Qian, additional, Meng, Rui, additional, Wu, Jingxun, additional, Zhang, Rui, additional, Zhou, Jin, additional, Zhu, Zhengfei, additional, Li, Yongheng, additional, Qiu, Hong, additional, Xia, Fan, additional, Lu, Yuanyuan, additional, Chen, Xiaofeng, additional, Ge, Rui, additional, Dai, Enyong, additional, Han, Yu, additional, Pan, Weiwei, additional, Pang, Fei, additional, He, Qingqing, additional, Huang, Jintao, additional, Wang, Kai, additional, Wu, Fan, additional, Xu, Bingwei, additional, Wang, Liping, additional, Zhu, Youcai, additional, Lin, Li, additional, Xie, Yanru, additional, Lin, Xinqing, additional, Cai, Jing, additional, Xu, Ling, additional, Li, Jisheng, additional, Jiao, Xiaodong, additional, Li, Kainan, additional, Wei, Jia, additional, Feng, Huijing, additional, Wang, Lin, additional, Du, Yingying, additional, Yao, Wang, additional, Shi, Xuefei, additional, Niu, Xiaomin, additional, Yuan, Dongmei, additional, Yao, Yanwen, additional, Huang, Jianhui, additional, Feng, Yue, additional, Zhang, Yinbin, additional, Sun, Pingli, additional, Wang, Hong, additional, Ye, Mingxiang, additional, Wang, Zhaofeng, additional, Hao, Yue, additional, Wang, Zhen, additional, Wan, Bin, additional, Lv, Donglai, additional, Yang, Shengjie, additional, Kang, Jin, additional, Zhang, Jiatao, additional, Zhang, Chao, additional, Ou, Juanjuan, additional, Shi, Lin, additional, Wang, Yina, additional, Li, Bihui, additional, Zhang, Zhang, additional, Li, Zhongwu, additional, Liu, Zhefeng, additional, Yang, Nong, additional, Wu, Lin, additional, Wang, Huijuan, additional, Jin, Gu, additional, Wang, Guansong, additional, Wang, Jiandong, additional, Fang, Meiyu, additional, Fang, Yong, additional, Li, Yuan, additional, Wang, Xiaojia, additional, Zhang, Yiping, additional, Zhu, Xixu, additional, Shen, Yi, additional, Ma, Shenglin, additional, Wang, Biyun, additional, Si, Lu, additional, Song, Yong, additional, Lu, Yuanzhi, additional, Chen, Jing, additional, and Song, Zhengbo, additional

Published
2024
Full Text
View/download PDF

16. Expert consensus on the diagnosis and treatment of RET gene fusion non‐small cell lung cancer in China

Author

Pu, Xingxiang, primary, Xu, Chunwei, additional, Wang, Qian, additional, Wang, Wenxian, additional, Wu, Fang, additional, Cai, Xiuyu, additional, Song, Zhengbo, additional, Yu, Jinpu, additional, Zhong, Wenzhao, additional, Wang, Zhijie, additional, Zhang, Yongchang, additional, Liu, Jingjing, additional, Zhang, Shirong, additional, Liu, Anwen, additional, Li, Wen, additional, Zhan, Ping, additional, Liu, Hongbing, additional, Lv, Tangfeng, additional, Miao, Liyun, additional, Min, Lingfeng, additional, Lin, Gen, additional, Huang, Long, additional, Yuan, Jingping, additional, Jiang, Zhansheng, additional, Rao, Chuangzhou, additional, Lv, Dongqing, additional, Yu, Zongyang, additional, Li, Xiaoyan, additional, Tang, Chuanhao, additional, Zhou, Chengzhi, additional, Zhang, Junping, additional, Guo, Hui, additional, Chu, Qian, additional, Meng, Rui, additional, Liu, Xuewen, additional, Wu, Jingxun, additional, Zhou, Jin, additional, Zhu, Zhengfei, additional, Pan, Weiwei, additional, Pang, Fei, additional, Huang, Jintao, additional, Wang, Kai, additional, Wu, Fan, additional, Shen, Tingting, additional, Zou, Shirui, additional, Xu, Bingwei, additional, Wang, Liping, additional, Zhu, Youcai, additional, Lin, Xinqing, additional, Cai, Jing, additional, Xu, Ling, additional, Li, Jisheng, additional, Jiao, Xiaodong, additional, Li, Kainan, additional, Feng, Huijing, additional, Wang, Lin, additional, Du, Yingying, additional, Yao, Wang, additional, Shi, Xuefei, additional, Niu, Xiaomin, additional, Yuan, Dongmei, additional, Yao, Yanwen, additional, Kang, Jing, additional, Zhang, Jiatao, additional, Zhang, Chao, additional, Fu, Jianfei, additional, Huang, Jianhui, additional, Zhang, Yinbin, additional, Sun, Pingli, additional, Wang, Hong, additional, Ye, Mingxiang, additional, Wang, Dong, additional, Wang, Zhaofeng, additional, Hao, Yue, additional, Wang, Zhen, additional, Wan, Bing, additional, Lv, Donglai, additional, Lan, Gang, additional, Yang, Shengjie, additional, Shi, Lin, additional, Wang, Yina, additional, Li, Bihui, additional, Zhang, Zhang, additional, Li, Zhongwu, additional, Li, Yuan, additional, Liu, Zhefeng, additional, Yang, Nong, additional, Wang, Huijuan, additional, Huang, Wenbin, additional, Hong, Zhuan, additional, Wang, Guansong, additional, Wang, Jiandong, additional, Fang, Meiyu, additional, Fang, Yong, additional, Zhu, Xixu, additional, Shen, Yi, additional, Zhang, Yiping, additional, Ma, Shenglin, additional, Song, Yong, additional, Lu, Yuanzhi, additional, Fang, Wenfeng, additional, Li, Ziming, additional, and Wu, Lin, additional

Published
2023
Full Text
View/download PDF

18. Virological and Mitochondriopathogical Characteristics of the SARS-CoV-2 Omicron XBB.1.16 Spike

Author

Fang, Liaoxin, Kang, Xiaofeng, Hong, Qian, Xue, Chunyuan, Pan, Lu, Chen, Jiaxin, Tang, Chuanhao, Sun, Liying, Xu, Xiaojie, Yuan, Jing, Du, Yimeng, and Xu, An

Abstract

The emergence of XBB.1.16 has gained rapid global prominence. Previous studies have elucidated that the infection of SARS-CoV-2 induces alterations in the mitochondrial integrity of host cells, subsequently influencing the cellular response to infection. In this study, we compared the differences in infectivity and pathogenicity between XBB.1.16 and the parental Omicron sublineages BA.1 and BA.2 and assessed their impact on host mitochondria. Our findings suggest that, in comparison with BA.1 and BA.2, XBB.1.16 exhibits more efficient spike protein cleavage, more efficient mediating syncytia formation, mild mitochondriopathy, and less pathogenicity. Altogether, our investigations suggest that, based on the mutation of key sites, XBB.1.16 exhibited enhanced infectivity but lower pathogenicity. This will help us to further investigate the biological functions of key mutation sites.

Published
2024
Full Text
View/download PDF

20. Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma

Author

Wang, Qian, primary, Xu, Chunwei, additional, Wang, Wenxian, additional, Zhang, Yongchang, additional, Li, Ziming, additional, Song, Zhengbo, additional, Wang, Jiandong, additional, Yu, Jinpu, additional, Liu, Jingjing, additional, Zhang, Shirong, additional, Cai, Xiuyu, additional, Li, Wen, additional, Zhan, Ping, additional, Liu, Hongbing, additional, Lv, Tangfeng, additional, Miao, Liyun, additional, Min, Lingfeng, additional, Li, Jiancheng, additional, Liu, Baogang, additional, Yuan, Jingping, additional, Jiang, Zhansheng, additional, Lin, Gen, additional, Chen, Xiaohui, additional, Pu, Xingxiang, additional, Rao, Chuangzhou, additional, Lv, Dongqing, additional, Yu, Zongyang, additional, Li, Xiaoyan, additional, Tang, Chuanhao, additional, Zhou, Chengzhi, additional, Zhang, Junping, additional, Guo, Hui, additional, Chu, Qian, additional, Meng, Rui, additional, Liu, Xuewen, additional, Wu, Jingxun, additional, Hu, Xiao, additional, Zhou, Jin, additional, Zhu, Zhengfei, additional, Chen, Xiaofeng, additional, Pan, Weiwei, additional, Pang, Fei, additional, Zhang, Wenpan, additional, Jian, Qijie, additional, Wang, Kai, additional, Wang, Liping, additional, Zhu, Youcai, additional, Yang, Guocai, additional, Lin, Xinqing, additional, Cai, Jing, additional, Feng, Huijing, additional, Wang, Lin, additional, Du, Yingying, additional, Yao, Wang, additional, Shi, Xuefei, additional, Niu, Xiaomin, additional, Yuan, Dongmei, additional, Yao, Yanwen, additional, Huang, Jianhui, additional, Wang, Xiaomin, additional, Zhang, Yinbin, additional, Sun, Pingli, additional, Wang, Hong, additional, Ye, Mingxiang, additional, Wang, Dong, additional, Wang, Zhaofeng, additional, Hao, Yue, additional, Wang, Zhen, additional, Wan, Bing, additional, Lv, Donglai, additional, Yu, Jianwei, additional, Kang, Jin, additional, Zhang, Jiatao, additional, Zhang, Chao, additional, Wu, Lixin, additional, Shi, Lin, additional, Ye, Leiguang, additional, Wang, Gaoming, additional, Wang, Yina, additional, Gao, Feng, additional, Huang, Jianfei, additional, Wang, Guifang, additional, Wei, Jianguo, additional, Huang, Long, additional, Li, Bihui, additional, Zhang, Zhang, additional, Li, Zhongwu, additional, Liu, Yueping, additional, Li, Yuan, additional, Liu, Zhefeng, additional, Yang, Nong, additional, Wu, Lin, additional, Wang, Qiming, additional, Huang, Wenbin, additional, Hong, Zhuan, additional, Wang, Guansong, additional, Qu, Fengli, additional, Fang, Meiyu, additional, Fang, Yong, additional, Zhu, Xixu, additional, Du, Kaiqi, additional, Ji, Jiansong, additional, Shen, Yi, additional, Chen, Jing, additional, Zhang, Yiping, additional, Ma, Shenglin, additional, Lu, Yuanzhi, additional, Song, Yong, additional, Liu, Anwen, additional, Zhong, Wenzhao, additional, and Fang, Wenfeng, additional

Published
2023
Full Text
View/download PDF

21. LINC00654 confers sorafenib resistance by suppressing ferroptosis via STAT3-mediated transcriptional activation of SLC7A11 in hepatocellular carcinoma

Author

Peng, Huanyan, primary, Xu, An, additional, Sun, Chao, additional, Tong, Fang, additional, Kang, Xiaofeng, additional, Zhou, Huifang, additional, Kang, Jiwen, additional, Li, Xingyu, additional, Han, Yuchen, additional, Xue, Chunyuan, additional, Tang, Chuanhao, additional, Fang, Liaoxin, additional, Du, Yimeng, additional, Han, Juqiang, additional, and Sun, Dianxing, additional

Published
2023
Full Text
View/download PDF

22. WITHDRAWN: Expert Consensus on the Diagnosis and Treatment of FGFR Gene-altered Solid Tumors

Author

Xu, Chunwei, Lian, Bin, Ou, Juanjuan, Wang, Qian, Wang, Wenxian, Wang, Ke, Wang, Dong, Song, Zhengbo, Liu, Aijun, Yu, Jinpu, Zhong, Wenzhao, Wang, Zhijie, Zhang, Yongchang, Liu, Jingjing, Zhang, Shirong, Cai, Xiuyu, Liu, Anwen, Li, Wen, Mao, Lili, Zhan, Ping, Liu, Hongbing, Lv, Tangfeng, Miao, Liyun, Min, Lingfeng, Chen, Yu, Yuan, Jingping, Wang, Feng, Jiang, Zhansheng, Lin, Gen, Huang, Long, Pu, Xingxiang, Lin, Rongbo, Liu, Weifeng, Rao, Chuangzhou, Lv, Dongqing, Yu, Zongyang, Li, Xiaoyan, Tang, Chuanhao, Zhou, Chengzhi, Zhang, Junping, Xue, Junli, Guo, Hui, Chu, Qian, Meng, Rui, Wu, Jingxun, Zhang, Rui, Zhou, Jin, Zhu, Zhengfei, Li, Yongheng, Qiu, Hong, Xia, Fan, Lu, Yuanyuan, Chen, Xiaofeng, Ge, Rui, Dai, Enyong, Han, Yu, Pan, Weiwei, Pang, Fei, Huang, Jintao, Wang, Kai, Wu, Fan, Xu, Bingwei, Wang, Liping, Zhu, Youcai, Lin, Li, Xie, Yanru, Lin, Xinqing, Cai, Jing, Xu, Ling, Li, Jisheng, Jiao, Xiaodong, Li, Kainan, Wei, Jia, Feng, Huijing, Wang, Lin, Du, Yingying, Yao, Wang, Shi, Xuefei, Niu, Xiaomin, Yuan, Dongmei, Yao, Yanwen, Huang, Jianhui, Feng, Yue, Zhang, Yinbin, Sun, Pingli, Wang, Hong, Ye, Mingxiang, Wang, Zhaofeng, Hao, Yue, Wang, Zhen, Wan, Bin, Lv, Donglai, Zhai, Zhanqiang, Yang, Shengjie, Kang, Jing, Zhang, Jiatao, Zhang, Chao, Shi, Lin, Wang, Yina, Li, Bihui, Zhang, Zhang, Li, Zhongwu, Liu, Zhefeng, Yang, Nong, Wu, Lin, Wang, Huijuan, Jin, Gu, Wang, Guansong, Wang, Jiandong, Fang, Meiyu, Fang, Yong, Li, Yuan, Wang, Xiaojia, Chen, Jing, Zhang, Yiping, Zhu, Xixu, Shen, Yi, Ma, Shenglin, Wang, Biyun, Si, Lu, Lu, Yuanzhi, Li, Ziming, Fang, Wenfeng, and Song, Yong

Published
2024
Full Text
View/download PDF

25. Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors

Author

Xu, Chunwei, primary, Zhang, Yongchang, additional, Wang, Wenxian, additional, Wang, Qian, additional, Li, Ziming, additional, Song, Zhengbo, additional, Wang, Jiandong, additional, Yu, Jinpu, additional, Liu, Jingjing, additional, Zhang, Shirong, additional, Cai, Xiuyu, additional, Wu, Ming, additional, Zhan, Ping, additional, Liu, Hongbing, additional, Lv, Tangfeng, additional, Miao, Liyun, additional, Min, Lingfeng, additional, Li, Jiancheng, additional, Liu, Baogang, additional, Yuan, Jingping, additional, Jiang, Zhansheng, additional, Lin, Gen, additional, Chen, Xiaohui, additional, Pu, Xingxiang, additional, Rao, Chuangzhou, additional, Lv, Dongqing, additional, Yu, Zongyang, additional, Li, Xiaoyan, additional, Tang, Chuanhao, additional, Zhou, Chengzhi, additional, Zhang, Junping, additional, Guo, Hui, additional, Chu, Qian, additional, Meng, Rui, additional, Liu, Xuewen, additional, Wu, Jingxun, additional, Hu, Xiao, additional, Fang, Min, additional, Zhou, Jin, additional, Zhu, Zhengfei, additional, Chen, Xiaofeng, additional, Pan, Weiwei, additional, Pang, Fei, additional, Zhou, Yuxiang, additional, Jian, Qijie, additional, Wang, Kai, additional, Wang, Liping, additional, Zhu, Youcai, additional, Yang, Guocai, additional, Lin, Xinqing, additional, Cai, Jing, additional, Liang, Lijun, additional, Feng, Huijing, additional, Wang, Lin, additional, Du, Yingying, additional, Yao, Wang, additional, Shi, Xuefei, additional, Niu, Xiaomin, additional, Yuan, Dongmei, additional, Yao, Yanwen, additional, Huang, Jianhui, additional, Zhang, Yinbin, additional, Sun, Pingli, additional, Wang, Hong, additional, Ye, Mingxiang, additional, Wang, Dong, additional, Wang, Zhaofeng, additional, Hao, Yue, additional, Wang, Zhen, additional, Wan, Bing, additional, Lv, Donglai, additional, Yu, Genhua, additional, Li, Anna, additional, Kang, Jin, additional, Zhang, Jiatao, additional, Zhang, Chao, additional, Chen, Huafei, additional, Shi, Lin, additional, Ye, Leiguang, additional, Wang, Gaoming, additional, Wang, Yina, additional, Gao, Feng, additional, Zhou, Wei, additional, Hu, Chunxiu, additional, Wei, Jianguo, additional, Li, Bihui, additional, Li, Zhongwu, additional, Li, Yuan, additional, Liu, Zhefeng, additional, Yang, Nong, additional, Wu, Lin, additional, Wang, Qiming, additional, Huang, Wenbin, additional, Hong, Zhuan, additional, Wang, Guansong, additional, Fang, Meiyu, additional, Fang, Yong, additional, Zhu, Xixu, additional, Du, Kaiqi, additional, Ji, Jiansong, additional, Shen, Yi, additional, Zhang, Yiping, additional, Ma, Shenglin, additional, Song, Yong, additional, Lu, Yuanzhi, additional, Liu, Anwen, additional, Fang, Wenfeng, additional, and Zhong, Wenzhao, additional

Published
2023
Full Text
View/download PDF

28. Chinese expert consensus on the diagnosis and treatment of HER2 ‐altered non–small cell lung cancer

Author

Zhang, Shirong, primary, Wang, Wenxian, additional, Xu, Chunwei, additional, Zhang, Yongchang, additional, Cai, Xiuyu, additional, Wang, Qian, additional, Song, Zhengbo, additional, Li, Ziming, additional, Yu, Jinpu, additional, Zhong, Wenzhao, additional, Wang, Zhijie, additional, Liu, Jingjing, additional, Liu, Anwen, additional, Li, Wen, additional, Zhan, Ping, additional, Liu, Hongbing, additional, Lv, Tangfeng, additional, Miao, Liyun, additional, Min, Lingfeng, additional, Lin, Gen, additional, Huang, Long, additional, Yuan, Jingping, additional, Jiang, Zhansheng, additional, Pu, Xingxiang, additional, Rao, Chuangzhou, additional, Lv, Dongqing, additional, Yu, Zongyang, additional, Li, Xiaoyan, additional, Tang, Chuanhao, additional, Zhou, Chengzhi, additional, Zhang, Junping, additional, Guo, Hui, additional, Chu, Qian, additional, Meng, Rui, additional, Liu, Xuewen, additional, Wu, Jingxun, additional, Zhou, Jin, additional, Zhu, Zhengfei, additional, Pan, Weiwei, additional, Dong, Xiaowei, additional, Pang, Fei, additional, Wang, Kai, additional, Yao, Chao, additional, Lin, Guomin, additional, Li, Site, additional, Yang, Zhi, additional, Luo, Jiancheng, additional, Jia, Hongtao, additional, Nie, Xiuqing, additional, Wang, Liping, additional, Zhu, Youcai, additional, Hu, Xiao, additional, Xie, Yanru, additional, Lin, Xinqing, additional, Cai, Jing, additional, Xia, Yang, additional, Feng, Huijing, additional, Wang, Lin, additional, Du, Yingying, additional, Yao, Wang, additional, Shi, Xuefei, additional, Niu, Xiaomin, additional, Yuan, Dongmei, additional, Yao, Yanwen, additional, Kang, Jing, additional, Zhang, Jiatao, additional, Zhang, Chao, additional, Gao, Wenbin, additional, Huang, Jianhui, additional, Zhang, Yinbin, additional, Sun, Pingli, additional, Wang, Hong, additional, Ye, Mingxiang, additional, Wang, Dong, additional, Wang, Zhaofeng, additional, Wan, Bing, additional, Lv, Donglai, additional, Yu, Genhua, additional, Shi, Lin, additional, Xia, Yuanli, additional, Gao, Feng, additional, Zhang, Xiaochen, additional, Xu, Tao, additional, Zhou, Wei, additional, Wang, Haixia, additional, Liu, Zhefeng, additional, Yang, Nong, additional, Wu, Lin, additional, Wang, Qiming, additional, Wang, Guansong, additional, Hong, Zhuan, additional, Wang, Jiandong, additional, Fang, Meiyu, additional, Fang, Yong, additional, Zhang, Yiping, additional, Song, Yong, additional, Ma, Shenglin, additional, Fang, Wenfeng, additional, and Lu, Yuanzhi, additional

Published
2022
Full Text
View/download PDF

29. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor

Author

Wang, Wenxian, primary, Wang, Qian, additional, Xu, Chunwei, additional, Li, Ziming, additional, Song, Zhengbo, additional, Zhang, Yongchang, additional, Cai, Xiuyu, additional, Zhang, Shirong, additional, Lian, Bin, additional, Li, Wen, additional, Liu, Anwen, additional, Zhan, Ping, additional, Liu, Hongbing, additional, Lv, Tangfeng, additional, Miao, Liyun, additional, Min, Lingfeng, additional, Chen, Yu, additional, Yuan, Jingping, additional, Wang, Feng, additional, Jiang, Zhansheng, additional, Lin, Gen, additional, Pu, Xingxiang, additional, Rao, Chuangzhou, additional, Lv, Dongqing, additional, Yu, Zongyang, additional, Li, Xiaoyan, additional, Tang, Chuanhao, additional, Zhou, Chengzhi, additional, Xie, Congying, additional, Zhang, Junping, additional, Guo, Hui, additional, Chu, Qian, additional, Meng, Rui, additional, Wu, Jingxun, additional, Zhang, Rui, additional, Wang, Liping, additional, Zhu, Youcai, additional, Hu, Xiao, additional, Xie, Yanru, additional, Lin, Xinqing, additional, Cai, Jing, additional, Lan, Fen, additional, Feng, Huijing, additional, Wang, Lin, additional, Yao, Wang, additional, Shi, Xuefei, additional, Huang, Jianhui, additional, Chen, Huafei, additional, Zhang, Yinbin, additional, Sun, Pingli, additional, Wan, Bing, additional, Pang, Fei, additional, Xu, Zanmei, additional, Wang, Kai, additional, Xia, Yuanli, additional, Ye, Mingxiang, additional, Wang, Dong, additional, Wei, Qing, additional, Feng, Shuitu, additional, Zhou, Jianya, additional, Zhang, Jiexia, additional, Lv, Donglai, additional, Gao, Wenbin, additional, Kang, Jing, additional, Yu, Genhua, additional, Liang, Xianbin, additional, Yu, Chengtao, additional, Shi, Lin, additional, Yang, Nong, additional, Wu, Lin, additional, Hong, Zhuan, additional, Hong, Wei, additional, Fang, Meiyu, additional, Zhang, Yiping, additional, Lu, Yuanzhi, additional, Wang, Guansong, additional, Ma, Shenglin, additional, Si, Lu, additional, Fang, Wenfeng, additional, and Song, Yong, additional

Published
2022
Full Text
View/download PDF

30. Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China

Author

Xu, Chunwei, primary, Si, Lu, additional, Wang, Wenxian, additional, Li, Ziming, additional, Song, Zhengbo, additional, Wang, Qian, additional, Liu, Aijun, additional, Yu, Jinpu, additional, Fang, Wenfeng, additional, Zhong, Wenzhao, additional, Wang, Zhijie, additional, Zhang, Yongchang, additional, Liu, Jingjing, additional, Zhang, Shirong, additional, Cai, Xiuyu, additional, Liu, Anwen, additional, Li, Wen, additional, Zhan, Ping, additional, Liu, Hongbing, additional, Lv, Tangfeng, additional, Miao, Liyun, additional, Min, Lingfeng, additional, Chen, Yu, additional, Yuan, Jingping, additional, Wang, Feng, additional, Jiang, Zhansheng, additional, Lin, Gen, additional, Pu, Xingxiang, additional, Lin, Rongbo, additional, Liu, Weifeng, additional, Rao, Chuangzhou, additional, Lv, Dongqing, additional, Yu, Zongyang, additional, Lei, Lei, additional, Li, Xiaoyan, additional, Tang, Chuanhao, additional, Zhou, Chengzhi, additional, Zhang, Junping, additional, Xue, Junli, additional, Guo, Hui, additional, Chu, Qian, additional, Meng, Rui, additional, Wu, Jingxun, additional, Zhang, Rui, additional, Hu, Xiao, additional, Zhou, Jin, additional, Zhu, Zhengfei, additional, Li, Yongheng, additional, Qiu, Hong, additional, Xia, Fan, additional, Lu, Yuanyuan, additional, Chen, Xiaofeng, additional, Ge, Rui, additional, Dai, Enyong, additional, Han, Yu, additional, Pan, Weiwei, additional, Luo, Jiancheng, additional, Jia, Hongtao, additional, Dong, Xiaowei, additional, Pang, Fei, additional, Wang, Kai, additional, Wang, Liping, additional, Zhu, Youcai, additional, Xie, Yanru, additional, Lin, Xinqin, additional, Cai, Jing, additional, Wei, Jia, additional, Lan, Fen, additional, Feng, Huijing, additional, Wang, Lin, additional, Du, Yingying, additional, Yao, Wang, additional, Shi, Xuefei, additional, Niu, Xiaomin, additional, Yuan, Dongmei, additional, Yao, Yanwen, additional, Huang, Jianhui, additional, Zhang, Yinbin, additional, Sun, Pingli, additional, Wang, Hong, additional, Ye, Mingxiang, additional, Wang, Dong, additional, Wang, Zhaofeng, additional, Wan, Bing, additional, Lv, Donglai, additional, Wei, Qing, additional, Kang, Jin, additional, Zhang, Jiatao, additional, Zhang, Chao, additional, Yu, Genhua, additional, Ou, Juanjuan, additional, Shi, Lin, additional, Li, Zhongwu, additional, Liu, Zhefeng, additional, Liu, Jing, additional, Yang, Nong, additional, Wu, Lin, additional, Wang, Huijuan, additional, Jin, Gu, additional, Yang, Liu, additional, Wang, Guansong, additional, Fang, Meiyu, additional, Fang, Yong, additional, Li, Yuan, additional, Wang, Xiaojia, additional, Zhang, Yiping, additional, Ma, Shenglin, additional, Wang, Biyun, additional, Zhang, Xiaotian, additional, Song, Yong, additional, and Lu, Yuanzhi, additional

Published
2022
Full Text
View/download PDF

39. Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report

Author

Guo, Ziwei, Meng, Chao, Wei, Xing, Tang, Chuanhao, and Liang, Jun

Subjects
nivolumab, TACE, Case Report, Cancer immunotherapy, Case Reports, small cell lung cancer
Abstract

The outcome of small cell lung cancer (SCLC) patients is poor because rapid metastasis develops after first‐line chemotherapy and few drugs are available for second‐line chemotherapy. The median survival rate has not significantly changed in recent years. In this report, we discuss the case of a 71‐year‐old Chinese female non‐smoker diagnosed with extensive‐stage SCLC who was treated with nivolumab for a short period and obtained a prolonged clinical benefit. We report the clinical history, clinical features, potential mechanism, benefits, and the best therapeutic window. The patient was treated with transcatheter arterial chemoembolization because of liver metastasis and then with four doses of nivolumab as third‐line systemic treatment. There was no disease progression for 15 months. The lesions became larger than before, suggesting disease progression, thus nivolumab treatment was ceased. Immunotherapy has the capacity to turn combined therapy into a feature that may be exploited for clinical benefit. Further research is required to evaluate whether combined treatment is beneficial for patients, affecting the efficacy of immunotherapy, and to determine the best therapeutic window for clinical treatment.

Published
2018

41. Morphology-Controlled Fabrication Strategy of Hollow Mesoporous Carbon Spheres@f-Fe2O3for Microwave Absorption and Infrared Stealth

Author

Ma, Wenjun, Tang, Chuanhao, He, Peng, Wu, Xiaohan, Cui, Zhong-Kai, Lin, Shaoliang, Liu, Xiaoyun, and Zhuang, Qixin

Abstract

The design and development of radar-–infrared compatible stealth materials are challenging in the field of broadband absorption due to the contradiction of stealth requirements and mechanisms in different frequency bands. However, hollow structures show great promise for multispectral stealth because they can lengthen the attenuation path of electromagnetic waves (EMWs) for microwave absorption, interrupt the continuity of heat-transport channels, and lower the thermal conductivity to realize infrared stealth. Here, a new morphological fabrication strategy has been developed to efficiently prepare compatible stealth nanomaterials. In a specific hydrothermal process, the confined growth of flake α-Fe2O3(f-Fe2O3) outside of hollow mesoporous carbon spheres (HMCS) is achieved using NH3·H2O as a shape-controlled reagent. The introduction of f-Fe2O3helps to lower infrared emissivity and improve high-frequency impedance matching, which depends on the stable dielectric property of the specific flake shape. Moreover, the size of f-Fe2O3can be regulated by changing the constituent proportion in the hydrothermal suspension to obtain excellent performance. The minimum reflection loss (RL) of the HMCS@f-Fe2O3-6 composite is −34.16 dB at 2.4 mm, and the effective absorption bandwidth (EAB) reaches 4.8 GHz. Furthermore, the lowest emissivities of the HMCS@f-Fe2O3-6-20 wt %/polyetherimide (PEI) film in the 3–5 and 8–14 μm infrared wavebands are 0.212 and 0.508, respectively. These discoveries may pave the way for the development of radar–infrared compatible stealth materials from the perspective of microstructural design.

Published
2022
Full Text
View/download PDF

45. Accurate Classification of Non-small Cell Lung Cancer (NSCLC) Pathology and Mapping of EGFR Mutation Spatial Distribution by Ambient Mass Spectrometry Imaging

Author

Zhang, Min, primary, He, Jiuming, additional, Li, Tiegang, additional, Hu, Haixu, additional, Li, Xiaofei, additional, Xing, Hao, additional, Wang, Jun, additional, Yang, Fan, additional, Ma, Qunfeng, additional, Liu, Bing, additional, Tang, Chuanhao, additional, Abliz, Zeper, additional, and Liu, Xiaoqing, additional

Published
2019
Full Text
View/download PDF

49. Cytoplasmic expression of estrogen receptor β may predict poor outcome of EGFR‑TKI therapy in metastatic lung adenocarcinoma

Author

Ding, Xiaosheng, primary, Li, Li, additional, Tang, CHuanhao, additional, Meng, Chao, additional, Xu, Weiran, additional, Wei, Xing, additional, Guo, Ziwei, additional, Zhang, Tingting, additional, Fu, Yali, additional, Zhang, Lingling, additional, Wang, Xiangyi, additional, Lin, Li, additional, and Liang, Jun, additional

Published
2018
Full Text
View/download PDF

50. Oral administration of sunitinib malate for long-term survival of a patient with multiple lung metastases from renal leiomyosarcoma

Author

Liu, Xiaoqing, Gao,Hongjun, Tang,Chuanhao, and Li,Xiaoyan

Subjects
urologic and male genital diseases, female genital diseases and pregnancy complications, OncoTargets and Therapy
Abstract

Xiaoyan Li, Hongjun Gao, Chuanhao Tang, Xiaoqing Liu Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, People’s Republic of China Abstract: Sunitinib, an oral tyrosine kinase inhibitor, has been approved by the US Food and Drug Administration for the treatment of metastatic renal cell carcinoma and imatinib-refractory gastrointestinal stromal tumor. In non-gastrointestinal stromal tumor soft tissue sarcomas, the activity of this small-molecule drug has been rarely reported. Herein, we report a patient with lung metastases from renal leiomyosarcoma who responded favorably to sunitinib after the failure of conventional chemotherapy. Adverse effects of sunitinib, which include fatigue, hand-foot syndrome, and stomatitis were observed following its administration. Withdrawal of sunitinib led to progression of disease, and resuming use of sunitinib was still effective for multiple lung metastases. Sunitinib might be an effective treatment for renal leiomyosarcoma, especially when conventional chemotherapy fails. Keywords: sunitinib, gastrointestinal stromal tumor, GIST, renal leiomyosarcoma

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results